Sanofi SA ( (SNY) ) has released its Q4 earnings. Here is a breakdown of the information Sanofi SA presented to its investors.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sanofi SA is a global biopharmaceutical company headquartered in Paris, specializing in the development and distribution of pharmaceutical products and vaccines, with a strong focus on innovation and research in various therapeutic areas including immunology, rare diseases, and oncology.
In the latest earnings report for Q4 2024, Sanofi SA revealed a 10.3% growth in sales at constant exchange rates (CER), with the company’s business earnings per share (EPS) surpassing the guidance for the year. Notably, the sales of Dupixent increased significantly, contributing to the overall sales performance.
Key highlights from the report include a total sales increase of 11.3% at CER for the fiscal year, reaching €41.1 billion. The pharmaceutical sector saw a robust performance with launches accounting for 8% of total sales, notably driven by the success of ALTUVIIIO. Additionally, there was a notable increase in vaccines sales, particularly Beyfortus achieving blockbuster status in its first full year. Sanofi’s commitment to research and development was evident with an expenditure rise to €7.4 billion, aligning with its strategic objectives.
Looking forward, Sanofi anticipates continued growth with expectations of mid to high single-digit sales increases and a strong rebound in business EPS in 2025. The company plans to continue its transformation towards a focused biopharma business, including the strategic sale of a controlling stake in its Opella consumer health segment, and remains optimistic about the potential of its expanding pipeline and upcoming product launches.
